オプションチェーンは、Apollomicsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Apollomicsの市場センチメントを評価します。.

Apollomics (NASDAQ:APLM) 株価情報, オプションチェーン

Apollomics

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Apollomics Inc. - Class A Ordinary Shares

Apollomics Inc

HF Foods Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFFG#NASDAQ">HFFG</a>) reported quarterly losses of $(0.83) per share. This is a 1760 percent decrease over earnings of $0.05 per share from the same period last year. The company reported $305.28 million in sales this quarter. This is a 8.69 percent increase over sales of $280.87 million the same period last year.

Earnings

News

HFFG

HF Foods Group Q4 EPS $(0.83) Down From $0.05 YoY, Sales $305.28M Up From $280.87M YoY

Warren Buffett's <a href="https://www.benzinga.com/real-estate">real-estate brokerage business</a>, HomeServices of America, is considering a deal with Compass.
What Happened: According <a href="https://www.wsj.com/real-estate/compass-in-talks-to-buy-warren-buffetts-real-estate-brokerage-unit-5eab82e5">to </a>The Wall Street Journal, Compass — the biggest U.S. brokerage by volume in 2023 — offered to buy HomeServices of America for an unknown price.
HomeServices of America is owned by Buffett&#8217;s Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>). It had about 820 brokerage offices and 270 franchisees in 2024.
It also owns Berkshire Hathaway HomeServices and Real Living.
See Also: <a href="https://www.benzinga.com/news/25/03/44238467/warren-buffett-shares-biggest-investing-mistakes-433m-deal-that-cost-berkshire-billions-and-trillion-dollar-tech-stocks-he-missed">Buffett Shares Biggest Investing Mistakes — $433M Deal That Cost Berkshire Billions And Trillion-Dollar Tech Stocks He Missed</a>
Why It Matters: The home-buying sector is consolidating. 
Earlier this week, Rocket Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44237879/rocket-redfin-deal-aims-to-create-end-to-end-real-estate-solution-where-does-that-leave-zillow">announced it will acquire</a> Redfin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) in a $1.75 billion deal.
Analysts anticipate the deal will increase competition between Zillow Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) and Rocket Companies, now bolstered by Redfin&#8217;s assets and capabilities. 
Now Read:<a href="https://www.benzinga.com/general/market-summary/25/03/44227856/nasdaq-sp-500-hit-6-month-lows-as-recession-fears-grow-whats-driving-markets-monday"> </a>
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44227856/nasdaq-sp-500-hit-6-month-lows-as-recession-fears-grow-whats-driving-markets-monday">Nasdaq, S&amp;P 500 Hit 6-Month Lows As Recession Fears Grow: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Image: Shutterstock

Real Estate

RDFN

Warren Buffett's Real Estate Brokerage, Compass Discuss Deal: Report

WIIM

AAOI

Applied Optoelectronics shares are trading higher after the company announced a warrant issuance agreement transaction with Amazon for 7,945,399 shares.

Pyxis Tankers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXS#NASDAQ">PXS</a>) reported quarterly sales of $12.035 million which beat the analyst consensus estimate of $10.500 million by 14.62 percent. This is a 9.16 percent decrease over sales of $13.249 million the same period last year.

Earnings Beats

Pyxis Tankers Q4 Sales $12.035M Beat $10.500M Estimate

Trading Ideas

Applied Optoelectronics Shares Resume Trade

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) shares traded lower Thursday as overall market weakness dragged down social media <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44311699/wall-streets-downward-slide-returns-gold-breaks-records-intel-skyrockets-on-ceo-appointment-whats-driving-markets-thursday">and tech stocks. </a>
What To Know: The decline came as Wall Street erased Wednesday's gains, with market sentiment weighed down <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44311699/wall-streets-downward-slide-returns-gold-breaks-records-intel-skyrockets-on-ceo-appointment-whats-driving-markets-thursday">by tariff threats and economic data. </a>
U.S. President Donald Trump's announcement of a potential <a href="https://www.benzinga.com/markets/25/03/44301836/trump-warns-of-200-tariff-on-french-champagne-and-eu-spirits-in-retaliation-to-europes-tariff-on-us-whiskey">200% tariff on European wine and spirits imports,</a> in response to the EU's 50% tariff on U.S. whiskey, added to global trade tensions. The uncertainty around tariffs raised fears of economic slowdowns and potential retaliatory measures, prompting investors to shift away from high-growth tech stocks.
The U.S. <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44300810/us-producer-inflation-stalls-in-february-as-services-items-decline-eggs-price-skyrockets">Producer Price Index</a> for February came in flat month-over-month, well below the expected 0.3% increase and the upwardly revised 0.6% gain in January. While weaker inflation data might typically support equities, the lack of growth raised concerns over consumer and business spending, further pressuring stocks.
The overall market downturn was reflected in the major indices, with the Dow Jones dropping 1.1%, the S&amp;P 500 falling 1.2% and the tech-heavy Nasdaq 100 sliding 1.7%. The sell-off was widespread, with every sector except materials trading in the red. Gold prices surged to a record $2,980 per ounce as investors sought safe-haven assets.
Why It Matters: Meta's stock decline aligns with broader tech sector struggles, as high-growth stocks are particularly sensitive to macroeconomic uncertainties. 
The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>), which includes Meta and other social media stocks, fell 2.06%, indicating that the pullback was industry-wide. The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) also dropped by 1.90%, showing broad weakness in tech companies.
The company's drop is also part of a broader trend of tech stocks facing volatility as investors rebalance portfolios away from riskier assets. As tariff concerns and macroeconomic pressures persist, Meta and other large-cap tech stocks could continue to face headwinds in the coming weeks.
META Price Action: Meta shares closed Thursday down 4.67% at $590.64 at the time of writing, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="537" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13161209/Screenshot-2025-03-13-at-16.11.38-1024x537.png" alt="" class="wp-image-823894" style="width:385px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13161209/Screenshot-2025-03-13-at-16.11.38-1024x537.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13161209/Screenshot-2025-03-13-at-16.11.38-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13161209/Screenshot-2025-03-13-at-16.11.38-768x403.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13161209/Screenshot-2025-03-13-at-16.11.38.png 1154w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/top-stories/25/03/44313558/nvidia-stock-reached-all-time-highs-after-jensen-huangs-ces-keynote-will-next-weeks-gtc-spark-another-surge">Nvidia Stock Reached All-Time Highs After Jensen Huang&#8217;s CES Keynote — Will Next Week&#8217;s GTC Spark Another Surge?</a></li>
</ul>
Photo: Shutterstock.

Movers

Tech

Meta Shares Drop During Market Sell-Off, Tariff Concerns: What's Going On?

Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.23) by 73.91 percent. This is a 5.26 percent decrease over losses of $(0.38) per share from the same period last year.

Earnings Misses

CADL

Candel Therapeutics Q4 EPS $(0.40) Misses $(0.23) Estimate

Dividends

W. P. Carey Increases Dividend From $0.88 To $0.89/Share

Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 39.62 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $4.188 which missed the analyst consensus estimate of $2.500 million by 100.00 percent. This is a 100.00 percent decrease over sales of $2.878 million the same period last year.

GBIO

Generation Bio Q4 2024 GAAP EPS $(0.32), Inline, Sales $4.188 Miss $2.500M Estimate

Pagaya Technologies Announces The Closing Of A $500M AAA-Rated Personal Loan ABS Transaction

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Receives Written Notice That It Was Not In Compliance With Nasdaq Listing Rule

PLBY

PLBY Group Q4 EPS $(0.15) Misses $(0.11) Estimate, Sales $33.49M

– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner –
– Three INDs for wholly-owned programs expected in the next 3 years, beginning with novel Tissue Factor ADC, STRO-004, planned for 2H 2025 –
– Jane Chung, President and COO, to succeed Bill Newell as CEO and Board Director –
– Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations –

Biotech

General

STRO

Sutro Biopharma Announces Strategic Portfolio Review; Results In Prioritization Of Next-Generation ADC Pipeline

Lake Street analyst Ben Klieve maintains Limoneira (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) with a Hold and lowers the price target from $25 to $23.

Price Target

Analyst Ratings

LMNR

Lake Street Maintains Hold on Limoneira, Lowers Price Target to $23

NAYA Biosciences, Inc.&nbsp;("NAYA") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture ("IVC") fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of&nbsp;12:01 a.m. Eastern Time on March 18, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on March 18, 2025, the Company's common stock will trade on a post-split basis under the same trading symbol, "NAYA".

Stock Split

NAYA

NAYA Announces 1-For-12 Reverse Stock Split Effective March 18, 2025

Management

SCNX

Scienture Holdings Appointed Eric Sherb As CFO

XPON

Xponential Fitness Q4 Adj. EPS $(0.19) Down From $(0.02) YoY

<ul>
<li>Board approves 15-for-1 stock split, subject to shareholder approval of share authorization increase</li>
<li>Split is aimed at helping team members take advantage of employee stock purchase benefits</li>
</ul>
SPRINGFIELD, Mo., March 13, 2025 (GLOBE NEWSWIRE) -- O'Reilly Automotive, Inc. (the "Company" or "O'Reilly") (Nasdaq: ORLY), a leading retailer in the automotive aftermarket industry, today announced that its Board of Directors (the "Board") approved a 15-for-1 split of its common stock, to be effected in the form of a one-time special stock dividend.
The stock split is subject to shareholder approval of an amendment to O'Reilly's Articles of Incorporation to increase the number of authorized shares of common stock to accommodate the stock split. O'Reilly intends to seek shareholder approval for this amendment at its upcoming annual meeting on May 15, 2025.

ORLY

O'Reilly Automotive Approves 15-For-1 Stock Split, Subject To Shareholder Approval Of An Increase In The Number Of Authorized Shares Of Common Stock At Its Upcoming Annual Meeting On May 15, 2025

Buybacks

KeyCorp Plans Purchase Up To $1.0B Of Common Shares In Open Market Or In Privately Negotiated Transactions

Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) reported quarterly sales of $83.220 million which beat the analyst consensus estimate of $81.120 million by 2.59 percent. This is a 7.73 percent decrease over sales of $90.195 million the same period last year.

XPOF

Xponential Fitness Q4 Sales $83.220M Beat $81.120M Estimate

Press Releases

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Biotech Sees Massive Buying Pressure Following Phase 2 Preliminary Data

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Health Care

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Comments

Apollomics

Apollomics (APLM) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル